← Back to Clinical Trials
Recruiting NCT07231822

NCT07231822 The Investigation of the Effectiveness of Virtual Reality Applications in Postmenopausal Osteoporosis Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07231822
Status Recruiting
Phase
Sponsor Kirsehir Ahi Evran Universitesi
Condition Osteoperosis
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-11-20
Primary Completion 2026-03-01

Trial Parameters

Condition Osteoperosis
Sponsor Kirsehir Ahi Evran Universitesi
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 40 Years
Max Age 65 Years
Start Date 2025-11-20
Completion 2026-03-01
Interventions
Conventional treatmentVirtual reality treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Osteoporosis is a progressive disease characterised by a decrease in bone mass, deterioration in bone microarchitecture, and increased fragility. Etiologically, it is divided into two types: primary (postmenopausal and senile) and secondary. Postmenopausal women are particularly at high risk; it is seen in more than 80% of women over the age of 50 and in almost all individuals over the age of 75. With menopause, bone mineral density decreases, which negatively affects neuromuscular functions, leading to balance disorders, decreased walking speed, and an increased risk of falls. Falls are the primary cause of osteoporotic fractures and result in functional loss, morbidity, mortality, and increased healthcare costs. Exercise is effective in reducing bone loss; in recent years, therapeutic virtual reality and exercise games (exergames) have come to the fore. However, the literature on the effectiveness of these applications in postmenopausal osteoporosis patients is limited. The aim of this study is to investigate the effects of virtual reality applications on balance, quality of life, and fall risk and to compare them with a control group.

Eligibility Criteria

Inclusion Criteria: * Postmenopausal women aged 50-75 years * Individuals diagnosed with osteoporosis based on Dual-Energy X-ray Absorptiometry (DEXA) measurement (T-score ≤ -2.5) * Having been in menopause for at least 1 year * Being able to walk independently (without the use of assistive devices) * Volunteering to participate in the study and having provided informed consent * Having adequate cognitive function (e.g., Mini Mental Test ≥ 24) Exclusion Criteria: * Secondary osteoporosis diagnosis (e.g. endocrine, metabolic or drug-induced causes) * History of lower limb fracture or surgical intervention within the last 6 months * Individuals with severe cardiovascular, neurological, or musculoskeletal disorders * Individuals with vestibular or visual impairments that may affect balance * Intolerance to virtual reality applications (e.g., dizziness, nausea, etc.) * Individuals who have participated in a regular physiotherapy or exercise programme within the last 3 months

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology